Background: Implantable loop recorders (ILRs) are effective in achieving symptom-rhythm correlation. However, diagnostic yield in routine clinical practice is not well established.
INTRODUCTION
Diagnosis of the underlying cause of episodic syncope, dizziness, and/or palpitations can be challenging. These episodes result from a variety of conditions and cardiac monitoring can help in teasing out rhythm-related causes such as bradyarrhythmias and tachyarrhythmias. Effective diagnosis of these conditions has the potential to change management and improve quality of life.
When suspecting an underlying bradyarrhythmia or tachyarrhythmia, healthcare providers often pursue a battery of tests including electrocardiography, 24-h Holter monitoring, or longer duration event monitoring. However, underdetection of infrequent events is common.
The limited diagnostic yield of existing monitors led to the development of implantable loop recorders (ILRs), which have the capacity to detect arrhythmias over the course of 2-3 years. Use of these devices has shown to improve detection of arrhythmias relevant to a host of clinical conditions. For example, ILR-guided cardiac monitoring can detect atrial fibrillation (AF) of >30 s duration in up to an additional 12.9% of ambulatory, otherwise previously undiagnosed patients, resulting in an incremental use of appropriate anticoagulation in up to 13 .6% of those patients, potentially in turn improving long-term stroke prevention. 1 In patients with unexplained syncope, ILR usage has been shown to be efficacious in diagnosis compared to patients undergoing conventional in-clinic evaluations, event or other limited period monitoring, and tilt-table testing. 1 While there are trial data available to support the utility of ILR in specific patient presentations, the diagnostic yield of ILR usage in routine practice is less well studied. Cardiovascular symptoms overlap at presentation. Current prospective studies may not account for many of these clinical situations. The diagnostic and therapeutic yield of ILR in patients presenting with a broad spectrum of symptoms has not been previously evaluated. However, given the potential costs of longerterm monitoring using an ILR device, it is of paramount importance to evaluate its value in aiding patient care.
We aimed to evaluate the diagnostic and therapeutic yield of cardiac monitoring with an ILR by performing a retrospective analysis of all patients implanted with an ILR at our tertiary care referral center.
METHODS

Study population and data collection
We reviewed the medical records of patients who underwent implan- 
Implantation approach
Loop recorder implants were all performed in an electrophysiology (EP) lab setting under sterile conditions with local anesthetic only, unless requested otherwise by the patient. They are performed with a plan for same-day discharge unless the patient is an inpatient already.
No prior skin preparation (eg, chlorhexidine skin washes) is performed on the night before operation. Prophylactic antibiotics are routinely used (one-single preincision dose of cefazolin unless allergy exists, in which case clindamycin is used).
Remote monitoring and verification of rhythm
All the implanted ILR devices were enrolled into the Carelink remote monitoring program with automatic arrhythmia detection programs and P sense algorithms switched "ON" when available. All the records of ILR-detected abnormal rhythm and symptom episodes transmitted by the patient are evaluated by a pacemaker nurse with physician oversight. Specifically, our center employs over a dozen full-time pacing nurses who take overnight calls and also are updated via an internal alert system whenever remote transmissions are submitted. These transmissions are reviewed by the pacing nurses who subsequently have a protocol in place to identify them as urgent (pauses confirmed to be actual asystole, ventricular arrhythmias, atrial arrhythmias with heart rate greater than 180) and the on-call electrophysiologist is notified, and the patients are called by the nurses to determine associated symptoms. In the case of all other transmissions, patients are called the next business day to identify correlating symptoms, and then the strips and data are supplied to the physician reviewing pacemaker reports that day and any relevant actions (patient follow-up to initiate medications, etc) are coordinated with administrative staff. Symptom-rhythm correlation was assessed for accuracy and changes in management following the event were recorded based on review of the clinical records.
Analysis
All analyses were performed by an independent observer blinded to the outcomes using SAS 9.4 software (SAS Institute, Cary, NC, USA). 
RESULTS
Patient characteristics
A total of 312 patients underwent ILR implantation over 5 ± 2 years. Mean age was 53 ± 22 years and 57% were men. The median CHADS2VaSc score was 1 (IQR = 1 -3). The baseline clinical and electrocardiogram characteristics in the study cohort are summarized in Table 1 AF = atrial fibrillation; COPD = chronic obstructive pulmonary disease; EF = ejection fraction; MI = myocardial infarction; SD = standard deviation; TIA = transient ischemic attack. 
Indications for implantation
Pre-ILR investigations
Most (91.3%) patients were evaluated for rhythm abnormalities using ambulatory monitoring before ILR implantation. Distribution of the various investigations done prior to the implantation of the ILR is shown in Figure 1 . 
Device details
A total of 159 (51%) patients were implanted with a Medtronic
Reveal XT device, whereas 153 (49%) patients were implanted with the Medtronic Linq device. Mean duration of follow-up was 13.9 ± 9.2 months. Device extraction data were available for 63 devices. The distribution of the reasons for removal is shown in Table 2 . Local pain and infection post-ILR implantation necessitating removal was noted in six patients. These patients were implanted with Medtronic Reveal XT devices.
Findings on monitoring
The distribution of the findings of monitoring is summarized in Supporting Information Figure 1 and Supporting Information Table 2 . A
TA B L E 2 Etiology for removal of the implantable loop recorder
Reason for removal Number n = 63 (%) Twenty (7%) patients had asymptomatic arrhythmias, of which AF was seen in two patients. More than one arrhythmia was seen in 23 (7.8%) patients during the monitoring period.
Symptomatic correlation with arrhythmia
In addition to the 18 patients lost to follow-up, seven (2.2%) patients did not provide details on symptoms during ILR monitoring (did not initiate remote monitoring and were not seen again at our center). A total of 163 (52.2%) patients had symptoms during the monitoring period.
Of these 163 symptomatic patients, 100 (32.1%) had correlation with an arrhythmia, whereas 63 (21.5%) patients had no correlation with an arrhythmia. In seven (1.9%) patients, this conclusion could not be drawn owing to the inability of the patient to correlate symptoms accurately (ie, lack of clarity on the timing of symptoms relative to timing of the recorded arrhythmia). (Figure 2 ).
Change in management post-ILR monitoring
Utility of ILR monitoring toward change in management
Overall, the indication that resulted in the highest rate of cardiac change in management was palpitations (56.3%), followed by syncope Figure 4A summarizes the changes in management resulting from ILR findings. Number needed to treat for a cardiac change in management was 4.9 while number needed to treat to result in an invasive intervention (eg, pacemaker, ICD) was 7.9
Condition-driven analysis 3.9.1 Syncope
( Figure 5 ).
Palpitations
A total of 51 patients of 312 (16.3%) patients had unexplained palpitations as an indication for ILR implantation. Thirty-three of fifty-one (64.7%) patients had an arrhythmia detected. Thirty of thirty-three (90.1%) patients reported symptoms and 21 of 33 (63.6%) patients had a correlation between symptoms and an arrhythmia. Figure 4B summarizes the changes in management occurring as a result of ILR findings.
Number needed to have a change in cardiac management was 2.8 and number needed to treat to result in an invasive intervention (ablation, pacemaker, ICD) was 8.5.
Cryptogenic stroke
In 27 patients, the indication for implantation of the ILR was cryptogenic stroke with a median CHADS2VASc score of 3 (IQR = 2-4). All were newly initiated on anticoagulation following the diagnosis of AF.
Pacemaker/ICD implantation
Twenty-three (11.2%) patients were implanted with a pacemaker after 
DISCUSSION
In this study, we report the therapeutic utility of ILR in a large cohort of patients who had failed conventional diagnostic testing for a variety of presumed cardiac symptoms. This study is the largest retrospective study to date in addressing the therapeutic benefit of ILR without limiting to a specific symptom indication. 1, 2 The main findings of the study are that in patients who underwent ILR, over a mean follow-up of 14 months, an arrhythmia was documented in 48% patients, with symptom arrhythmia correlation noted in 32% patients. This led to a change in cardiac management in 42%
patients with a number needed to result in a change in management respectively.
An ILR provides the opportunity for longer-term monitoring in patients with symptoms or conditions presumed to be of an arrhythmic origin. ILR implantation has been reviewed and evaluated in a variety of clinical situations, including unexplained syncope, palpitations, and other presentations that could suggest an arrhythmic cause. [2] [3] [4] Prior data have suggested that early rather than late implantation of ILR in patients undergoing evaluation for syncope helps in the reduction of hospitalization and morbidity (53% vs 75%, P value < 0.001). 5 The age distribution of patients evaluated in this study was lower compared to patients evaluated in the PICTURE registry as well as the EaSyAs, 1 EGSYS2, 6 and ISSUE 2 7 syncope studies. In addition, to a number needed to treat of 2.1, a majority of whom (62, 42.5%) had a change in cardiac management. When limited to syncope alone, 77 (39%) patients had a change in management after ILR implantation, correlating to a number needed to treat of 2.5. When limited to palpitations alone, 32 (63%) patients had a change in management after ILR implantation, correlating to a number needed to treat of 1.6.
Potential for a change in management
After failing a battery of conventional tests to effect management, 47%
patients had a directed change in management with ILR. In a multivariate analysis, the preimplantation indication of syncope (odds ratio
[OR] = 2.06; confidence intervals [CI] = 1.17-3.67; P value = 0.01) and male gender (OR = 2.14; CI = 1.33-3.49; P value = 0.002) were associated with a significant impact on the possibility of change in management post-ILR monitoring (Table 3) .
Role in cryptogenic stroke
When limited to cryptogenic stroke, nearly 20% of patients had an AF diagnosis. This was similar to the findings seen in the study by Gladstone et al. 10 Ziegler et al in their review of the de-identified Medtronic Discovery Link database also detected AF at a median duration of 112 days in 21% of patients postcryptogenic stroke with better results seen using continuous monitoring over intermittent monitoring. 11 Brachmann et al concluded that the longer the time over which continuous monitoring was performed, the higher the yield of diagnosing AF in the CRYSTAL-AF study. 13 Ziegler reproduced the same results in a real-world cohort. 14 A total of 26 % of all our patients underwent monitoring for > 12 months before the absence of AF was concluded. Cessation of monitoring was determined by a combination of factors including patient preference, physician decision, and results of continued follow-up. The CHADS2VaSc scores of those with cryptogenic stroke receiving ILR in our population was similar to that seen in the CRYSTAL-AF study. 15 
Symptom-rhythm correlation
Therapy was changed based on ILR monitoring in most patients who reported symptoms during monitoring. Our results showed more frequent changes in management than in the PICTURE registry but similar to the study by Krahn et al. 16 The predictive accuracy of the device to rule out cardiac causes in symptomatic patients was similarly high arrhythmias. 17 One limitation of our study is how one defines the duration of AF needed to be regarded as "clinically significant." While robust evidence is present for the significance of AF > 24 h, 18 it is unclear how shorter episodes contribute to strokes. [19] [20] [21] [22] [23] 
Limitations
Our study has several limitations. This is a single-center retrospective design with no randomization and no comparison group. The findings may be unique to our center and reflect institutional practice patterns.
Our study did not address cost and did not allow us to characterize which of the subgroups would benefit most from ILR monitoring in a cost-effective manner due to varying insurers and levels of payment.
However, this has been studied in a microcosting study by Edvardsson et al who concluded that avoiding repetition and early prescription of testing (such as ambulatory monitoring) were important considerations in choosing when to implant an ILR when attempting to reduce costs. 24 They recommended a standard structured testing format prior to implantation to maximize cost efficacy of long-term monitoring. We were unable to evaluate this in our study.
CONCLUSIONS
In a large cohort of patients, ILR implantation provided diagnostic and therapeutic guidance in 48% and 47% of patients, respectively. Nearly one out of every two patients with a change of management had a cardiac-specific therapy implemented due to ILR monitoring. These findings confirm the utility of ILR in patients with single or multiple symptoms of a possible arrhythmic etiology.
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